Nosocomial bloodstream infections due to viridans streptococci in haematological and non-haematological patients: species distribution and antimicrobial resistance

J Antimicrob Chemother. 2004 Apr;53(4):631-4. doi: 10.1093/jac/dkh159. Epub 2004 Mar 10.

Abstract

Objectives: We studied the species distribution and antimicrobial susceptibility of viridans streptococci (VS) isolates causing nosocomial bloodstream infections (BSIs) in Finnish hospitals.

Patients and methods: Patients with nosocomial BSIs due to VS were identified through a hospital-wide prospective laboratory-based surveillance in two university and two regional hospitals during September 1998-August 2001. Isolates of VS were sent to the reference laboratory for species confirmation and antimicrobial susceptibility testing.

Results: A total of 2038 nosocomial BSIs were identified; 108 (5%) of the BSIs were caused by VS. Of the VS BSIs, 66% were in patients with a haematological malignancy, 14% in patients with a solid tumour and 18% in patients who had undergone surgery preceding the infection. The most common species group identified was Streptococcus mitis (82%). High-level penicillin resistance (> or = 4 mg/L) and cefotaxime resistance (> or = 4mg/L) were present in 5% and 4% of isolates, respectively; both were detected only in haematological patients. However, in non-haematological patients, resistance to erythromycin (17%), and reduced susceptibility to levofloxacin (14%) and penicillin (19%) were common.

Conclusions: The resistance problems in VS are not limited to haematological patients. These findings may have significant clinical implications in the choice of both empirical antibiotic and antimicrobial prophylaxis regimens.

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use
  • Bacteremia / drug therapy*
  • Bacteremia / epidemiology
  • Bacteremia / microbiology
  • Cross Infection / drug therapy*
  • Cross Infection / epidemiology
  • Cross Infection / microbiology
  • Drug Resistance, Bacterial / drug effects
  • Drug Resistance, Bacterial / physiology*
  • Hematologic Neoplasms / epidemiology
  • Hematologic Neoplasms / microbiology*
  • Humans
  • Microbial Sensitivity Tests / statistics & numerical data
  • Population Surveillance / methods
  • Prospective Studies
  • Streptococcal Infections / drug therapy*
  • Streptococcal Infections / epidemiology
  • Streptococcal Infections / microbiology
  • Viridans Streptococci / drug effects*
  • Viridans Streptococci / growth & development

Substances

  • Anti-Infective Agents